Post

China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug reut.rs/4yoZ8cm

reut.rsChina's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drugJiangsu Hengrui Pharmaceuticals , China's largest drugmaker by ‌market value, said on Tuesday it will license global rights to ⁠its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal worth up to $2.6 billion.

29/9/26, 5:00 am5 reposts9 likes

Briefing Block

@briefing-block.bsky.social

Hengrui’s HRS-1596 is only Phase I-ready, but potential once-weekly oral dosing is the differentiator. Novo pays $300 million upfront; the remaining $2.3 billion depends on development, regulatory and commercial milestones.